Advertisement

Journal of Neurology

, Volume 259, Issue 9, pp 1994–2008 | Cite as

Rehabilitation interventions in multiple sclerosis: an overview

  • Serafin BeerEmail author
  • Fary Khan
  • Jürg Kesselring
Medical Progress in the Journal of Neurology

Abstract

Multiple sclerosis is a complex, heterogeneous disease associated with long-term disability. Despite the availability of advanced disease-modifying and symptomatic therapies that may decrease activity and progression of disease and alleviate complaints to a certain extent, there is still a need for comprehensive rehabilitation interventions in order to reduce sequels and symptoms of the disease on personal activities and social participation to achieve the highest possible independence and the best quality of life. Timing and setting of rehabilitation interventions should be selected individually depending on disease phase, functional deficits, personal requirements, as well as specific goals. In addition, limitations and disease-specific characteristics that may influence rehabilitation outcome should be noted. Rehabilitation interventions should be considered early for maintaining functional capacity and reducing risk for losing important abilities or independence. Due to gradual failure of adaptive compensatory mechanisms along the course of disease, benefits of rehabilitation interventions are generally higher in earlier phases of MS. Inpatient and outpatient multidisciplinary rehabilitation has been shown to be beneficial in improving disability, participation and quality of life despite progression of the disease. Good evidence exists for different specific interventions improving physical and cognitive performance. Other important issues responsible for beneficial effects of comprehensive rehabilitation in MS include education, instruction, and information of patients and caregivers. Comprehensive assessment of health domains in MS patients using standardized framework and common language for describing the impact of disease at different levels, using International Classification of Functioning, Disability and Health (ICF) core sets may increase the knowledge of needs of these patients for more efficient and adapted rehabilitation interventions meeting these individual requirements, and promote perception and acceptance of rehabilitation as a valuable treatment option in MS. ICF core sets may increase the knowledge of more efficient and adapted rehabilitation measures meeting more properly individual requirements, and promote perception and acceptance of rehabilitation as a valuable treatment option in MS.

Keywords

Multiple sclerosis Comprehensive management Multidisciplinary rehabilitation Specific rehabilitative interventions 

Notes

Conflicts of interest

We declare that we have no conflicts of interest.

References

  1. 1.
    Koch-Henriksen N, Sorensen PS (2010) The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 9:520–532PubMedCrossRefGoogle Scholar
  2. 2.
    Alonso A, Hernan MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71:129–135PubMedCrossRefGoogle Scholar
  3. 3.
    Bentzen J, Flachs EM, Stenager E, Bronnum-Hansen H, Koch-Henriksen N (2010) Prevalence of multiple sclerosis in Denmark 1950–2005. Mult Scler 16:520–525PubMedCrossRefGoogle Scholar
  4. 4.
    Chitnis T, Glanz B, Jaffin S, Healy B (2009) Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 15:627–631PubMedCrossRefGoogle Scholar
  5. 5.
    Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6:903–912PubMedCrossRefGoogle Scholar
  6. 6.
    Lassmann H, Bruck W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218PubMedCrossRefGoogle Scholar
  7. 7.
    Koutsis G, Evangelopoulos ME, Andreadou E, Mandellos D, Karachalios G, Potagas C, Karantoni E, Karouli M, Chrysovitsanou C, Vassilopoulos D, Sfagos C (2010) The onset of multiple sclerosis in Greece: a single-center study of 1,034 consecutive patients. Eur Neurol 63:350–356PubMedCrossRefGoogle Scholar
  8. 8.
    Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M (2007) Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 6:887–902PubMedCrossRefGoogle Scholar
  9. 9.
    Martinelli V, Rodegher M, Moiola L, Comi G (2004) Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 25(Suppl 4):S350–S355PubMedCrossRefGoogle Scholar
  10. 10.
    Hurwitz BJ (2011) Analysis of current multiple sclerosis registries. Neurology 76:S7–S13PubMedCrossRefGoogle Scholar
  11. 11.
    Kesselring J, Beer S (2005) Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 4:643–652PubMedCrossRefGoogle Scholar
  12. 12.
    Pfleger CC, Flachs EM, Koch-Henriksen N (2010) Social consequences of multiple sclerosis (1): early pension and temporary unemployment–a historical prospective cohort study. Mult Scler 16:121–126PubMedCrossRefGoogle Scholar
  13. 13.
    Pfleger CC, Flachs EM, Koch-Henriksen N (2010) Social consequences of multiple sclerosis. Part 2. Divorce and separation: a historical prospective cohort study. Mult Scler 16:878–882PubMedCrossRefGoogle Scholar
  14. 14.
    Kesselring J (2010) Disease progression in multiple sclerosis. I. Impaired mobility and its impact on limitations of activities and social participation. Eur Neurol Rev 5:56–60Google Scholar
  15. 15.
    Kobelt G, Berg J, Atherly D, Hadjimichael O (2006) Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 66:1696–1702PubMedCrossRefGoogle Scholar
  16. 16.
    Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B (2006) Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 77:918–926PubMedCrossRefGoogle Scholar
  17. 17.
    Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT (2005) Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 11:232–239PubMedCrossRefGoogle Scholar
  18. 18.
    Compston DAS, Milligan NM, Hughes PJ, Gibbs J, McBroom V, Morgan BP, Campbell AK (1987) A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 2. laboratory results. J Neurol Neurosurg Psychiatry 50:517–522PubMedCrossRefGoogle Scholar
  19. 19.
    Milligan NM, Newcombe R, Compston DAS (1987) A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. J Neurol Neurosurg Psychiatry 50:511–516PubMedCrossRefGoogle Scholar
  20. 20.
    Sloka JS, Stefanelli M (2005) The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 11:425–432PubMedCrossRefGoogle Scholar
  21. 21.
    Wingerchuk DM (2008) Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol 28:56–68PubMedCrossRefGoogle Scholar
  22. 22.
    Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8:987–997PubMedCrossRefGoogle Scholar
  23. 23.
    Bates D (2011) Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 76:S14–S25PubMedCrossRefGoogle Scholar
  24. 24.
    Rieckmann P, Traboulsee A, Devonshire V, Oger J (2008) Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord 1:181–192PubMedCrossRefGoogle Scholar
  25. 25.
    Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med 362:387–401PubMedCrossRefGoogle Scholar
  26. 26.
    Freedman MS (2011) Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 76:26–34CrossRefGoogle Scholar
  27. 27.
    Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O’Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 8:254–260PubMedCrossRefGoogle Scholar
  28. 28.
    Bar-Or A, Rieckmann P, Traboulsee A, Yong VW (2011) Targeting progressive neuroaxonal injury: lessons from multiple sclerosis. CNS Drugs 25:783–799PubMedCrossRefGoogle Scholar
  29. 29.
    Paltamaa J, Sarasoja T, Wikstrom J, Malkia E (2006) Physical functioning in multiple sclerosis: a population-based study in central Finland. J Rehabil Med 38:339–345PubMedCrossRefGoogle Scholar
  30. 30.
    Thompson AJ, Toosy AT, Ciccarelli O (2010) Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 9:1182–1199PubMedCrossRefGoogle Scholar
  31. 31.
    Erwin A, Gudesblatt M, Bethoux F, Bennett SE, Koelbel S, Plunkett R, Sadiq S, Stevenson VL, Thomas AM, Tornatore C, Zaffaroni M, Hughes M (2011) Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler 17:623–629PubMedCrossRefGoogle Scholar
  32. 32.
    Stetkarova I, Yablon SA, Kofler M, Stokic DS (2010) Procedure- and device-related complications of intrathecal baclofen administration for management of adult muscle hypertonia: a review. Neurorehabil Neural Repair 24:609–619PubMedCrossRefGoogle Scholar
  33. 33.
    Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B et al (2000) Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, placebo-controlled, dose-ranging study. J Neurol Neurosurg Psychiatry 68:707–712PubMedCrossRefGoogle Scholar
  34. 34.
    Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C (2004) Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 218:103–108PubMedCrossRefGoogle Scholar
  35. 35.
    Barnes MP (2006) Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 7:607–615PubMedCrossRefGoogle Scholar
  36. 36.
    Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O’Leary C, Ratcliffe S, Novakova I, Zapletalova O, Pikova J, Ambler Z (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32:451–459PubMedCrossRefGoogle Scholar
  37. 37.
    Mills RJ, Yap L, Young CA (2007) Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev 1:CD005029PubMedGoogle Scholar
  38. 38.
    Timmermann L, Deuschl G, Fogel W, Hilker R, Kupsch A, Lange M, Schrader C, Sixel-Doring F, Volkmann J, Benecke R (2009) Tiefe Hirnstimulation bei Multiple-Sklerose-Tremor: Empfehlungen der Arbeitsgemeinschaft Tiefe Hirnstimulation. Nervenarzt 80:673–677PubMedCrossRefGoogle Scholar
  39. 39.
    Judge SI, Bever CT Jr (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111:224–259PubMedCrossRefGoogle Scholar
  40. 40.
    Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373:732–738PubMedCrossRefGoogle Scholar
  41. 41.
    Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, Carlesimo GA, Zibellini G, Caltagirone C (2001) Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 7:354–358PubMedGoogle Scholar
  42. 42.
    Kos D, Kerckhofs E, Nagels G, D’Hooghe MB, Ilsbroukx S (2008) Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 22:91–100PubMedGoogle Scholar
  43. 43.
    Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN (2002) Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72:179–183PubMedCrossRefGoogle Scholar
  44. 44.
    Lange R, Volkmer M, Heesen C, Liepert J (2009) Modafinil effects in multiple sclerosis patients with fatigue. J Neurol 256:645–650PubMedCrossRefGoogle Scholar
  45. 45.
    Brown JN, Howard CA, Kemp DW (2010) Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother 44:1098–1103PubMedCrossRefGoogle Scholar
  46. 46.
    Littleton ET, Hobart JC, Palace J (2010) Modafinil for multiple sclerosis fatigue: does it work? Clin Neurol Neurosurg 112:29–31PubMedCrossRefGoogle Scholar
  47. 47.
    Pucci E, Branas P, D’Amico R, Giuliani G, Solari A, Taus C (2007) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 14:CD002818Google Scholar
  48. 48.
    MacAllister WS, Belman AL, Milazzo M, Weisbrot DM, Christodoulou C, Scherl WF, Preston TE, Cianciulli C, Krupp LB (2005) Cognitive functioning in children and adolescents with multiple sclerosis. Neurology 64:1422–1425PubMedCrossRefGoogle Scholar
  49. 49.
    Khan F, Turner-Stokes L, Stevermuer T, Simmonds F (2009) Multiple sclerosis rehabilitation outcomes: analysis of a national casemix data set from Australia. Mult Scler 15:869–875PubMedCrossRefGoogle Scholar
  50. 50.
    Khan F, Pallant JF, Pallant JI, Brand C, Kilpatrick TJ (2010) A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry 81:1033–1038PubMedCrossRefGoogle Scholar
  51. 51.
    Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, Lucas M, Macleod N, Mangnall J, North A, Porter B, Reid S, Russell N, Watkiss K, Wells M (2009) A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 80:470–477PubMedGoogle Scholar
  52. 52.
    Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, Fowler CJ (2007) Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 62:452–457PubMedCrossRefGoogle Scholar
  53. 53.
    Mehnert U, Birzele J, Reuter K, Schurch B (2010) The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol 184:1011–1016PubMedCrossRefGoogle Scholar
  54. 54.
    Jepson RG, Mihaljevic L, Craig J (2004) Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 1:CD001321PubMedGoogle Scholar
  55. 55.
    Zivadinov R, Zorzon M, Bosco A, Bragadin LM, Moretti R, Bonfigli L, Iona LG, Cazzato G (1999) Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 5:428–431PubMedGoogle Scholar
  56. 56.
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. New Eng J Med 338:1397–1404PubMedCrossRefGoogle Scholar
  57. 57.
    DasGupta R, Fowler CJ (2003) Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 63:153–166PubMedCrossRefGoogle Scholar
  58. 58.
    Vidal J, Curcoll L, Roig T, Bagunya J (1995) Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients. Revista de neurologia 23:269–271PubMedGoogle Scholar
  59. 59.
    Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE (2004) Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63:1579–1585PubMedCrossRefGoogle Scholar
  60. 60.
    Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB (2006) Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 245:127–136PubMedCrossRefGoogle Scholar
  61. 61.
    Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De Keyser J (2011) Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev 2:CD007295PubMedGoogle Scholar
  62. 62.
    Wade DT (1992) Measurement in neurological rehabilitation. Oxford University Press, OxfordGoogle Scholar
  63. 63.
    Steins SA, O’Brien B, Young M (1997) The person, disablement and the process of rehabilitation. In: Steins SA, O’Brien B, Young M (eds) PM& R Secrets. Hanley & Belfus, Philidelphia, pp 1–8Google Scholar
  64. 64.
    World Health Organization (WHO) (2001) International classification of functioning, disability and health (ICF). WHO, GenevaGoogle Scholar
  65. 65.
    Khan F, Pallant JF, Zhang N, Turner-Stokes L (2010) Clinical practice improvement approach in multiple sclerosis rehabilitation: a pilot study. Int J Rehabil Res 33:238–247PubMedCrossRefGoogle Scholar
  66. 66.
    Khan F, Turner-Stokes L, Ng L, Kilpatrick T, Amatya B (2011) Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev 1:CD006036Google Scholar
  67. 67.
    Craig J, Young CA, Ennis M, Baker G, Boggild M (2003) A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry 74:1225–1230PubMedCrossRefGoogle Scholar
  68. 68.
    Liu C, Playford ED, Thompson AJ (2003) Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis? J Neurol 250:1214–1218PubMedCrossRefGoogle Scholar
  69. 69.
    Langdon DW, Thompson AJ (1999) Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mult Scler 5:94–100PubMedGoogle Scholar
  70. 70.
    Grasso MG, Troisi E, Rizzi F, Morelli D, Paolucci S (2005) Prognostic factors in multidisciplinary rehabilitation treatment in multiple sclerosis: an outcome study. Mult Scler 11:719–724PubMedCrossRefGoogle Scholar
  71. 71.
    Uhthoff W (1890) Untersuchungen über die bei der multiplen Herdsklerose vorkommenden Augenstörungen. Arch Psychiat Nervenkr 21:303–410Google Scholar
  72. 72.
    Smith KJ, McDonald WI (1999) The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 354:1649–1673PubMedCrossRefGoogle Scholar
  73. 73.
    Humm AM, Beer S, Kool J, Magistris MR, Kesselring J, Rosler KM (2004) Quantification of Uhthoff’s phenomenon in multiple sclerosis: a magnetic stimulation study. Clin Neurophysiol (Official Journal of the International Federation of Clinical Neurophysiology) 115:2493–2501CrossRefGoogle Scholar
  74. 74.
    Sheean GL, Murray NMF, Rothwell JC, Miller DH, Thompson AJ (1997) An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 120:299–315PubMedCrossRefGoogle Scholar
  75. 75.
    Dalgas U, Stenager E, Ingemann-Hansen T (2008) Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler 14:35–53PubMedCrossRefGoogle Scholar
  76. 76.
    Smith RM, Adeney-Steel M, Fulcher G, Longley WA (2006) Symptom change with exercise is a temporary phenomenon for people with multiple sclerosis. Arch Phys Med Rehabil 87:723–727PubMedCrossRefGoogle Scholar
  77. 77.
    Bjarnadottir OH, Konradsdottir AD, Reynisdottir K, Olafsson E (2007) Multiple sclerosis and brief moderate exercise: a randomised study. Mult Scler 13:776–782PubMedCrossRefGoogle Scholar
  78. 78.
    Rocca MA, Falini A, Colombo B, Scotti G, Comi G, Filippi M (2002) Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. Ann Neurol 51:330–339PubMedCrossRefGoogle Scholar
  79. 79.
    Cifelli A, Matthews PM (2002) Cerebral plasticity in multiple sclerosis: insights from fMRI. Mult Scler 8:193–199PubMedCrossRefGoogle Scholar
  80. 80.
    Thickbroom GW, Sacco P, Faulkner DL, Kermode AG, Mastaglia FL (2008) Enhanced corticomotor excitability with dynamic fatiguing exercise of the lower limb in multiple sclerosis. J Neurol 255:1001–1005PubMedCrossRefGoogle Scholar
  81. 81.
    Penner IK, Opwis K, Kappos L (2007) Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis. J Neurol 254(Suppl 2):II53–II57PubMedCrossRefGoogle Scholar
  82. 82.
    Heesen C, Romberg A, Gold S, Schulz KH (2006) Physical exercise in multiple sclerosis: supportive care or a putative disease-modifying treatment. Expert Rev Neurother 6:347–355PubMedCrossRefGoogle Scholar
  83. 83.
    Freeman JA, Langdon DW, Hobart JC, Thompson AJ (1999) Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 52:50–56PubMedCrossRefGoogle Scholar
  84. 84.
    World Health Organization (WHO) (2004) Comunity based rehabilitation: a strategy for rehabilitation, equalization of opportunities, poverty reduction and social Inclusion of people with disabilities. WHO Library Joint Position Paper 2004Google Scholar
  85. 85.
    Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability rating scale (EDSS). Neurology 13:1444–1452CrossRefGoogle Scholar
  86. 86.
    Twork S, Wiesmeth S, Spindler M, Wirtz M, Schipper S, Pohlau D, Klewer J, Kugler J (2010) Disability status and quality of life in multiple sclerosis: non-linearity of the expanded disability status scale (EDSS). Health Qual Life Outcomes 8:55PubMedCrossRefGoogle Scholar
  87. 87.
    van Winsen LM, Kragt JJ, Hoogervorst EL, Polman CH, Uitdehaag BM (2010) Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Mult Scler 16:604–610PubMedCrossRefGoogle Scholar
  88. 88.
    Cadavid D, Tang Y, O’Neill G (2010) Responsiveness of the expanded disability status scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Revista de neurologia 51:321–329PubMedGoogle Scholar
  89. 89.
    Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ (2004) Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess 8(iii):1–48Google Scholar
  90. 90.
    Kesselring J, Coenen M, Cieza A, Thompson A, Kostanjsek N, Stucki G (2008) Developing the ICF Core Sets for multiple sclerosis to specify functioning. Mult Scler 14:252–254PubMedCrossRefGoogle Scholar
  91. 91.
    Coenen M, Cieza A, Freeman J, Khan F, Miller D, Weise A, Kesselring J (2011) The development of ICF Core Sets for multiple sclerosis: results of the international consensus conference. J Neurol 258:1477–1488PubMedCrossRefGoogle Scholar
  92. 92.
    National Institute for Clinical Excellence (NICE) (2003) Management of multiple sclerosis in primary and secondary care. Clinical guidelines 8. NICE, LondonGoogle Scholar
  93. 93.
    Department of Health (2005) The national service framework (NSF) for long-term conditions. Department of Health, LondonGoogle Scholar
  94. 94.
    Motl RW, McAuley E, Snook EM (2005) Physical activity and multiple sclerosis: a meta-analysis. Mult Scler 11:459–463PubMedCrossRefGoogle Scholar
  95. 95.
    Motl RW, Snook EM, McAuley E, Scott JA, Hinkle ML (2007) Demographic correlates of physical activity in individuals with multiple sclerosis. Disabil Rehabil 29:1301–1304PubMedCrossRefGoogle Scholar
  96. 96.
    Doerksen SE, Motl RW, McAuley E (2007) Environmental correlates of physical activity in multiple sclerosis: a cross-sectional study. Int J Behav Nutr Phys Act 4:49PubMedCrossRefGoogle Scholar
  97. 97.
    National Health and Medical Research Council (NHMRC) (2009) NHMRC levels of evidence and grades for recommendations for developers of guidelines. In: NHMRCGoogle Scholar
  98. 98.
    Stuifbergen AK, Blozis SA, Harrison TC, Becker HA (2006) Exercise, functional limitations, and quality of life: a longitudinal study of persons with multiple sclerosis. Arch Phys Med Rehabil 87:935–943PubMedCrossRefGoogle Scholar
  99. 99.
    Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G (2011) Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev:CD003980Google Scholar
  100. 100.
    Snook EM, Motl RW (2009) Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabilitation Neural Repair 23:108–116PubMedCrossRefGoogle Scholar
  101. 101.
    Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T (2009) Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 73:1478–1484PubMedCrossRefGoogle Scholar
  102. 102.
    Dalgas U, Stenager E, Jakobsen J, Petersen T, Overgaard K, Ingemann-Hansen T (2010) Muscle fiber size increases following resistance training in multiple sclerosis. Mult Scler 16:1367–1376PubMedCrossRefGoogle Scholar
  103. 103.
    Rasova K, Havrdova E, Brandejsky P, Zalisova M, Foubikova B, Martinkova P (2006) Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. Mult Scler 12:227–234PubMedCrossRefGoogle Scholar
  104. 104.
    McAuley E, Motl RW, Morris KS, Hu L, Doerksen SE, Elavsky S, Konopack JF (2007) Enhancing physical activity adherence and well-being in multiple sclerosis: a randomised controlled trial. Mult Scler 13:652–659PubMedCrossRefGoogle Scholar
  105. 105.
    van den Berg M, Dawes H, Wade DT, Newman M, Burridge J, Izadi H, Sackley CM (2006) Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. J Neurol Neurosurg Psychiatry 77:531–533PubMedCrossRefGoogle Scholar
  106. 106.
    Giesser B, Beres-Jones J, Budovitch A, Herlihy E, Harkema S (2007) Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler 13:224–231PubMedCrossRefGoogle Scholar
  107. 107.
    Newman MA, Dawes H, van den Berg M, Wade DT, Burridge J, Izadi H (2007) Can aerobic treadmill training reduce the effort of walking and fatigue in people with multiple sclerosis: a pilot study. Mult Scler 13:113–119PubMedCrossRefGoogle Scholar
  108. 108.
    Pilutti LA, Lelli DA, Paulseth JE, Crome M, Jiang S, Rathbone MP, Hicks AL (2011) Effects of 12 weeks of supported treadmill training on functional ability and quality of life in progressive multiple sclerosis: a pilot study. Arch Phys Med Rehabil 92:31–36PubMedCrossRefGoogle Scholar
  109. 109.
    Beer S, Aschbacher B, Manoglou D, Gamper E, Kool J, Kesselring J (2008) Robot-assisted gait training in multiple sclerosis: a pilot randomized trial. Mult Scler 14:231–236PubMedCrossRefGoogle Scholar
  110. 110.
    Schwartz I, Sajin A, Moreh E, Fisher I, Neeb M, Forest A, Vaknin-Dembinsky A, Karussis D, Meiner Z (2011) Robot-assisted gait training in multiple sclerosis patients: a randomized trial. Mult Scler [Epub ahead of print]Google Scholar
  111. 111.
    Künzle U (2000) Schweizer Studie über die Wirksamkeit der Hippotherapie-K bei Multiple-Sklerose-Patienten: Hippotherapie. Springer, Berlin Heidelberg New York, pp 359–381Google Scholar
  112. 112.
    Bronson C, Brewerton K, Ong J, Palanca C, Sullivan SJ (2010) Does hippotherapy improve balance in persons with multiple sclerosis: a systematic review. Eur J Phys Rehabil Med 46:347–353PubMedGoogle Scholar
  113. 113.
    Silkwood-Sherer D, Warmbier H (2007) Effects of hippotherapy on postural stability, in persons with multiple sclerosis: a pilot study. J Neurol Phys Ther 31:77–84PubMedGoogle Scholar
  114. 114.
    Gamper UN (1995) Wasserspezifische Bewegungstherapie und Training. Gustav Fischer Verlag, StuttgartGoogle Scholar
  115. 115.
    Kesiktas N, Paker N, Erdogan N, Gulsen G, Bicki D, Yilmaz H (2004) The use of hydrotherapy for the management of spasticity. Neurorehabilitation Neural Repair 18:268–273PubMedCrossRefGoogle Scholar
  116. 116.
    Salem Y, Scott AH, Karpatkin H, Concert G, Haller L, Kaminsky E, Weisbrot R, Spatz E (2011) Community-based group aquatic programme for individuals with multiple sclerosis: a pilot study. Disabil Rehabil 33:720–728PubMedCrossRefGoogle Scholar
  117. 117.
    Castro-Sánchez AM, Matarán-Peñarrocha GA, Lara-Palomo I, Saavedra-Hernández M, Arroyo-Morales M, Moreno-Lorenzo C (2012) Hydrotherapy for the treatment of pain in people with multiple sclerosis: a randomized controlled trial. Evid Based Complement Alternat Med [Epub ahead of print]Google Scholar
  118. 118.
    Beenakker EA, Oparina TI, Hartgring A, Teelken A, Arutjunyan AV, De Keyser J (2001) Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology 57:892–894PubMedCrossRefGoogle Scholar
  119. 119.
    White AT, Wilson TE, Davis SL, Petajan JH (2000) Effect of precooling on physical performance in multiple sclerosis. Mult Scler 6:176–180PubMedGoogle Scholar
  120. 120.
    Warke K, Al-Smadi J, Baxter D, Walsh DM, Lowe-Strong AS (2006) Efficacy of transcutaneous electrical nerve stimulation (tens) for chronic low-back pain in a multiple sclerosis population: a randomized, placebo-controlled clinical trial. Clin J Pain 22:812–819PubMedCrossRefGoogle Scholar
  121. 121.
    Al-Smadi J, Warke K, Wilson I, Cramp AF, Noble G, Walsh DM, Lowe-Strong AS (2003) A pilot investigation of the hypoalgesic effects of transcutaneous electrical nerve stimulation upon low back pain in people with multiple sclerosis. Clin Rehabil 17:742–749PubMedCrossRefGoogle Scholar
  122. 122.
    Steultjens EM, Dekker J, Bouter LM, Cardol M, Van de Nes JC, Van den Ende CH (2009) Occupational therapy for multiple sclerosis. Cochrane Database Syst Rev 1:CD003608Google Scholar
  123. 123.
    Baker NA, Tickle-Degnen L (2001) The effectiveness of physical, psychological, and functional interventions in treating clients with multiple sclerosis: a meta-analysis. Am J Occup Ther 55:324–331PubMedCrossRefGoogle Scholar
  124. 124.
    Souza A, Kelleher A, Cooper R, Cooper RA, Iezzoni LI, Collins DM (2010) Multiple sclerosis and mobility-related assistive technology: systematic review of literature. J Rehabil Res Dev 47:213–223PubMedCrossRefGoogle Scholar
  125. 125.
    Bartholome G (1999) Schluckstörungen. In: Frommelt P, Grötzbach H (eds) Neurorehabilitation. Blackwell Wissenschafts-Verlag, Berlin Wien, pp 107–124Google Scholar
  126. 126.
    Prosiegel M, Heintze M, Wagner-Sonntag E, Hannig C, Wuttge-Hannig A, Yassouridis A (2002) Schluckstörungen bei neurologischen Patienten: Eine prospektive Studie zu Diagnostik, Störungsmustern, Therapie und Outcome. Nervenarzt 73:364–370PubMedCrossRefGoogle Scholar
  127. 127.
    Gosselink R, Kovacs L, Ketelaer P, Carton H, Decramer M (2000) Respiratory muscle weakness and respiratory muscle training in severely disabled multiple sclerosis patients. Arch Phys Med Rehabil 81:747–751PubMedGoogle Scholar
  128. 128.
    Chiara T, Martin D, Sapienza C (2007) Expiratory muscle strength training: speech production outcomes in patients with multiple sclerosis. Neurorehabilitation Neural Repair 21:239–249PubMedCrossRefGoogle Scholar
  129. 129.
    Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151PubMedCrossRefGoogle Scholar
  130. 130.
    Rosti-Otajarvi EM, Hamalainen PI (2011) Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev 11:CD009131PubMedGoogle Scholar
  131. 131.
    Thomas PW, Thomas S, Hillier C, Galvin K, Baker R (2009) Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev 1:CD004431Google Scholar
  132. 132.
    Forman AC, Lincoln NB (2010) Evaluation of an adjustment group for people with multiple sclerosis: a pilot randomized controlled trial. Clin Rehabil 24:211–221PubMedCrossRefGoogle Scholar
  133. 133.
    O’Brien AR, Chiaravalloti N, Goverover Y, Deluca J (2008) Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 89:761–769PubMedCrossRefGoogle Scholar
  134. 134.
    Mattioli F, Stampatori C, Bellomi F, Capra R, Rocca M, Filippi M (2010) Neuropsychological rehabilitation in adult multiple sclerosis. Neurol Sci 31:S271–S274PubMedCrossRefGoogle Scholar
  135. 135.
    Benedict RH, Shapiro A, Priore R, Miller C, Munschauer F, Jacobs L (2000) Neuropsychological counseling improves social behavior in cognitively-impaired multiple sclerosis patients. Mult Scler 6:391–396PubMedGoogle Scholar
  136. 136.
    Lincoln NB, Dent A, Harding J, Weyman N, Nicholl C, Blumhardt LD, Playford ED (2002) Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psychiatry 72:93–98PubMedCrossRefGoogle Scholar
  137. 137.
    Cosio D, Jin L, Siddique J, Mohr DC (2011) The effect of telephone-administered cognitive-behavioral therapy on quality of life among patients with multiple sclerosis. Ann Behav Med 41:227–234PubMedCrossRefGoogle Scholar
  138. 138.
    van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E (2008) A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med 70:205–213PubMedCrossRefGoogle Scholar
  139. 139.
    Khan F, Ng L, Turner-Stokes L (2011) Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis. Cochrane Database Syst Rev 1:CD007256Google Scholar
  140. 140.
    Pantano P, Mainero C, Caramia F (2006) Functional brain reorganization in multiple sclerosis: evidence from fMRI studies. J Neuroimaging 16:104–114PubMedCrossRefGoogle Scholar
  141. 141.
    Finkelstein J, Wood J (2009) Design and implementation of Home Automated Telemanagement system for patients with multiple sclerosis. Conf Proc IEEE Eng Med Biol Soc 2009:6091–6094PubMedGoogle Scholar
  142. 142.
    Mori F, Ljoka C, Magni E, Codeca C, Kusayanagi H, Monteleone F, Sancesario A, Bernardi G, Koch G, Foti C, Centonze D (2011) Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol 258(7):1281–1287PubMedCrossRefGoogle Scholar
  143. 143.
    Judica E, Martinelli Boneschi F, Ungaro D, Comola M, Gatti R, Comi G, Rossi P (2011) Impact of fatigue on the efficacy of rehabilitation in multiple sclerosis. J Neurol 258:835–839PubMedCrossRefGoogle Scholar
  144. 144.
    Sacco R, Bussman R, Oesch P, Kesselring J, Beer S (2011) Assessment of gait parameters and fatigue in MS patients during inpatient rehabilitation: a pilot trial. J Neurol 258:889–894PubMedCrossRefGoogle Scholar
  145. 145.
    Di Fabio RP, Soderberg J, Choi T, Hansen CR, Schapiro RT (1998) Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil 79:141–146PubMedCrossRefGoogle Scholar
  146. 146.
    Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C (2000) Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 4:1–61PubMedGoogle Scholar
  147. 147.
    Andreasen AK, Stenager E, Dalgas U (2011) The effect of exercise therapy on fatigue in multiple sclerosis. Mult Scler 17:1041–1054PubMedCrossRefGoogle Scholar
  148. 148.
    Neill J, Belan I, Ried K (2006) Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs 56:617–635PubMedCrossRefGoogle Scholar
  149. 149.
    Huntley A, Ernst E (2000) Complementary and alternative therapies for treating multiple sclerosis symptoms: a systematic review. Complement Ther Med 8:97–105PubMedCrossRefGoogle Scholar
  150. 150.
    de Carvalho ML, Motta R, Konrad G, Battaglia MA, Brichetto G (2012) A randomized placebo-controlled cross-over study using a low-frequency magnetic field in the treatment of fatigue in multiple sclerosis. Mult Scler 18:82–89PubMedCrossRefGoogle Scholar
  151. 151.
    Bovend’Eerdt TJ, Minelli C, Newman M et al (2008) The effects of stretching in spasticity: a systematic review. Arch Phys Med Rehabil 89:1395–1406PubMedCrossRefGoogle Scholar
  152. 152.
    Vahtera T, Haaranen M, Viramo-Koskela AL, Ruutiainen J (1997) Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil 11:211–219PubMedCrossRefGoogle Scholar
  153. 153.
    Lúcio AC, Perissinoto MC, Natalin RA, Prudente A, Damasceno BP, D’ancona CA (2011) A comparative study of pelvic floor muscle training in women with multiple sclerosis: its impact on lower urinary tract symptoms and quality of life. Clinics (Sao Paulo) 66:1563–1568CrossRefGoogle Scholar
  154. 154.
    DasGupta P, Haslam C, Goodwin R, Fowler CJ (1997) The ‘Queen Square bladder stimulator’: a device for assisting emptying of the neurogenic bladder. Br J Urol 80:234–237PubMedCrossRefGoogle Scholar
  155. 155.
    Prasad RS, Smith SJ, Wright H (2003) Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 17:42–47PubMedCrossRefGoogle Scholar
  156. 156.
    Blackmore DE, Hart SL, Albiani JJ, Mohr DC (2011) Improvements in partner support predict sexual satisfaction among individuals with multiple sclerosis. Rehabil Psychol 56:117–122PubMedCrossRefGoogle Scholar
  157. 157.
    Fletcher SG, Castro-Borrero W, Remington G, Treadaway K, Lemack GE, Frohman EM (2009) Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol 6:96–107PubMedCrossRefGoogle Scholar
  158. 158.
    Wiles CM (2008) Physiotherapy and related activities in multiple sclerosis. Mult Scler 14:863–871PubMedCrossRefGoogle Scholar
  159. 159.
    Sabapathy NM, Minahan CL, Turner GT, Broadley SA (2011) Comparing endurance- and resistance-exercise training in people with multiple sclerosis: a randomized pilot study. Clin Rehabil 25:14–24PubMedCrossRefGoogle Scholar
  160. 160.
    Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW (1996) Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 39:432–441PubMedCrossRefGoogle Scholar
  161. 161.
    Mostert S, Kesselring J (2002) Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 8:161–168PubMedCrossRefGoogle Scholar
  162. 162.
    Kileff J, Ashburn A (2005) A pilot study of the effect of aerobic exercise on people with moderate disability multiple sclerosis. Clin Rehabil 19:165–169PubMedCrossRefGoogle Scholar
  163. 163.
    Rampello A, Franceschini M, Piepoli M, Antenucci R, Lenti G, Olivieri D, Chetta A (2007) Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlled study. Phys Ther 87:545–555, discussion 555-549PubMedCrossRefGoogle Scholar
  164. 164.
    Lo AC, Triche EW (2008) Improving gait in multiple sclerosis using robot-assisted, body weight supported treadmill training. Neurorehabilitation Neural Repair 22:661–671PubMedCrossRefGoogle Scholar
  165. 165.
    Wier LM, Hatcher MS, Triche EW, Lo AC (2011) Effect of robot-assisted versus conventional body-weight-supported treadmill training on quality of life for people with multiple sclerosis. J Rehabil Res Dev 48:483–492PubMedCrossRefGoogle Scholar
  166. 166.
    Nilsagard Y, Denison E, Gunnarsson LG (2006) Evaluation of a single session with cooling garment for persons with multiple sclerosis–a randomized trial. Disabil Rehabil Assist Technol 1:225–233PubMedCrossRefGoogle Scholar
  167. 167.
    Meyer-Heim A, Rothmaier M, Weder M, Kool J, Schenk P, Kesselring J (2007) Advanced lightweight cooling-garment technology: functional improvements in thermosensitive patients with multiple sclerosis. Mult Scler 13:232–237PubMedCrossRefGoogle Scholar
  168. 168.
    Fowler CJ (2010) The effectiveness of bladder rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 81:944PubMedCrossRefGoogle Scholar
  169. 169.
    Miller L, Mattison P, Wood P, Wood L (2007) The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 13:527–533Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Department of Neurology and NeurorehabilitationRehabilitation CenterValensSwitzerland
  2. 2.Department of Rehabilitation MedicineUniversity of Melbourne, Royal Melbourne HospitalMelbourneAustralia

Personalised recommendations